Fujifilm Healthcare

Japanese imaging + healthcare IT manufacturer. Origin: X-ray film + photographic products. Medical imaging division grew through organic development + strategic acquisitions. Acquired Hitachi Healthcare in 2021, significantly expanding the imaging portfolio.

Company history

• 1934 — Fujifilm founded in Japan.
• 2000s — Fujifilm's photographic-film business contracts; strategic pivot to healthcare, specialty chemicals.
• 2006 — acquires Toyama Chemical (pharmaceuticals).
• 2018 — launches Sonosite acquisition (ultrasound).
• 2021 — acquires Hitachi's Diagnostic Imaging business for ~$1.6 billion. Hitachi's MRI, CT, and ultrasound product lines roll into Fujifilm Healthcare.

Product line by modality

• Mammography — ASPIRE Cristalle (2D + tomo + biopsy)
• Digital radiography — FDR series (DR rooms), FDR Go PLUS (mobile DR)
• CR — long history of computed-radiography readers (now legacy)
• Ultrasound — Sonosite (point-of-care ultrasound — handheld + portable), plus Hitachi-lineage Aloka / Arietta systems
• MRI — Hitachi-lineage Echelon / Airis / Oasis (open + low/mid-field MRI)
• CT — Hitachi-lineage Supria / Scenaria systems
• Endoscopy — Fujifilm's traditional endoscope business
• PACS / enterprise imaging — Synapse (enterprise-grade PACS, strong global share)

Market position

Leader in point-of-care ultrasound (via Sonosite). Strong in mammography (ASPIRE Cristalle competitive with Hologic Selenia / 3Dimensions). Post-Hitachi acquisition, meaningful presence in MRI + CT. Synapse PACS is a top-3 global enterprise imaging platform.